Kelun-Biotech’s OptiTROP-Lung06 sacituzumab tirumotecan plus pembrolizumab improves PFS in Phase III NSCLC trial

Direct company-distributed and wire reports support a genuine Phase III clinical result rather than market commentary: OptiTROP-Lung06 met its primary progression-free-survival endpoint, with BICR-assessed risk of progression or death reduced by 51% (HR 0.49; 95% CI 0.36–0.65) and an overall-survival trend favoring the combination. This is a material, forward-looking late-stage catalyst for Kelun-Biotech, Merck & Co.’s sac-TMT collaboration, and competing TROP2 programs, so it is approved as a clinical_study development. Importance is high because the result may affect regulatory review and future commercialization, while surprise is moderated because no explicit market consensus is provided. Confidence is very high for the core trial result; the timestamp uses the contemporaneous October 25, 2026 disclosure as the best available estimate because the exact time of the underlying endpoint determination is not stated. The prior duplicate consolidation and new-event classification are retained. The TradingView wire is included as an additional explicit source. Generic CDMOs are excluded as stakeholders because no sac-TMT-specific manufacturing relationship is disclosed.